13F Holdings
中文EN

ALNY ALNYLAM PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1178670 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY65.2%
TTM net income YoY239.7%
TTM EPS YoY206.9%
Revenue 3-yr CAGR53.0%
Net income 3-yr CAGR—

Margins

Gross margin81.8%
Operating margin13.5%
Net margin10.5%
FCF margin11.8%
EBITDA margin15.0%

Returns

ROE90.8%
ROA8.4%
ROIC (approx.)—
Asset turnover0.81x

Leverage & solvency

Liabilities / assets84.1%
Debt / equity0.00x
Current ratio2.76x
Interest coverage1.58x

Cash quality & payout

Operating cash flow / net income1.28x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue1.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$3.71B$2.25B$1.83B$1.04B$844.29M
Cost of revenue$677.17M$306.51M$268.22M$140.17M$115.00M
Gross profit$3.04B$1.94B$1.56B$897.24M$729.28M
R&D expense$1.32B$1.13B$1.00B$883.01M$792.16M
SG&A expense$1.21B$975.53M$795.65M$770.66M$620.64M
Operating income$501.58M-$176.88M-$282.18M-$785.07M-$708.65M
Interest expense$252.63M$141.86M$121.22M$155.97M$143.02M
Pretax income$323.15M-$377.38M-$433.52M-$1.13B-$852.14M
Income tax$9.40M-$99.22M$6.72M$4.16M$680,000
Net income$313.75M-$278.16M-$440.24M-$1.13B-$852.82M
EBITDA$557.24M-$120.22M-$228.12M-$740.60M-$661.09M
EPS (basic)2.39-2.18-3.52-9.30-7.20
EPS (diluted)2.33-2.18-3.52-9.30-7.20
Weighted avg. shares (diluted)134.68M127.65M124.91M121.69M118.45M
Balance sheet
Cash & equivalents$1.66B$968.65M$812.69M$868.56M$822.15M
Short-term investments$1.25B$1.72B$1.62B$1.30B$1.55B
Receivables$777.57M$405.31M$327.79M$237.96M$198.57M
Inventory$82.72M$78.51M$89.15M$128.96M$86.36M
Current assets$4.05B$3.30B$2.98B$2.69B$2.81B
PP&E, net$513.15M$502.78M$526.06M$523.49M$501.96M
Total assets$4.97B$4.24B$3.83B$3.55B$3.64B
Current liabilities$1.47B$1.19B$967.79M$767.91M$695.71M
Long-term debt————$675.70M
Total debt————$675.70M
Total liabilities$4.18B$4.17B$4.05B$3.70B$3.06B
Shareholders' equity$789.18M$67.09M-$220.64M-$158.22M$588.20M
Net debt————-$146.46M
Shares outstanding132.38M129.29M125.79M123.92M120.18M
Cash flow statement
Operating cash flow$524.08M-$8.31M$104.16M-$541.27M-$641.69M
Capital expenditure$58.70M$34.28M$62.21M$72.06M$76.37M
Free cash flow$465.38M-$42.59M$41.95M-$613.33M-$718.07M
Investing cash flow$436.33M-$116.84M-$336.35M$169.35M-$273.30M
Financing cash flow-$305.19M$294.16M$172.13M$425.75M$1.25B
Depreciation & amortization$55.66M$56.67M$54.05M$44.47M$47.57M
Stock-based compensation$348.24M$272.08M$221.68M$230.65M$165.72M

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.